Elevating the future of cancer care with alpha theranostics
Project factsheets
Learn more about the projects supported by IHI as well as the Innovative Medicines Initiative (IMI).
Displaying 91 projects and 4 programmes
Real-world implementation, deployment and validation of early detection tools and lifestyle enhancement
Imaging for patient benefit in arthritis
Biomarker research and evaluation for clinical implementation and supporting systems enhancement
Collaborative action and research for engagement, persistence and adherence in treatment & health
Clinical impact through AI-assisted MS care
Combining diagnostic data and interventional approaches for futureproof cardiology care
Easy workflow integration for gene therapy
European action for the diagnosis of early non-symptomatic type 1 diabetes for intervention
Propelling the shift toward the future of circular, safe and sustainable packaging and single use device ecoDesigned solutions through healthcare environments
EuroHeartPath: Leading innovation in cardiovascular pathways for improved patient outcomes
Bridging gaps in cardiac health management
Testing, improving, and co-creating guidance and tools for real world evidence generation in europe and use for decision-making in Europe: GREG
GRIP on MASH: global research initiative for patient screening on MASH
Guiding multi-modal therapies against MRD by liquid biopsies
Harmonised approach to early feasibility studies for medical devices in the European Union
Individualised care from early risk of cardiovascular disease to established heart failure
Integration of heterogeneous data and evidence towards regulatory and HTA acceptance
Increasing lutetium production, while leveraging metabolic imaging to enhance theranostics effectiveness
Imaging and advanced guidance for workflow optimization in interventional oncology
Framework to IMPROVE the integration of patient generated health data to facilitate value based healthcare
Verification and validation of a biomarker panel that identifies individuals at high risk to develop Crohn’s disease allowing interception of full-blown disease development
A biomarker-based platform for early diagnosis of chronic liver disease to enable personalized therapy
Reducing non-human primates in non-clinical safety assessment: The European initiative on minipig and micropig models
Patient lifestyle and disease data interactium
Advancing safe and sustainable by design practices in pharmaceutical manufacturing
Prediction of Alzheimer’s disease using an AI driven screening platform
Patient-centric blood sampling for improved healthcare (Project-COMFORT)
Precision medicine platform in neurodegenerative disease
Research in Europe and diversity inclusion
Comprehensive methodological and operational approach to clinical trials in rare and ultra-rare diseases
Improving patient outcomes and reducing cognitive load of clinical staff in intensive care through medical-device interoperability and an open and secure IT ecosystem
Synthetic healthcare data governance hub
Smart human-centred effortless support for professional clinical applications
Synthetic data generation framework for integrated validation of use cases and AI healthcare applications
Theranostics ecosystem for personalised care
Unleashing a comprehensive, holistic and patient centric stroke management for a better, rapid, advanced and personalised stroke diagnosis, treatment and outcome prediction
Developing and implementing virtual control groups to reduce animal use in toxicology research
Virus related biomarkers to improve management of chronic conditions
Identification of the molecular mechanisms of non-response to treatments, relapses and remission in autoimmune, inflammatory, and allergic conditions
Autism Innovative Medicine Studies – 2 – Trials
Antimicrobial Resistance Accelerator
Accelerating research & development for advanced therapies
Big Data for Better Outcomes
Behavioral and adherence model for improving quality, health outcomes and cost-effectiveness of healthcare
Big data @ heart
Central repository for digital pathology
Biomarkers in atopic dermatitis and psoriasis
conect4children - Collaborative network for European clinical trials for children
Cardiomyopathy in type 2 diabetes mellitus
Corona accelerated R&D in Europe
Collaboration for prevention and treatment of MDR bacterial infections
Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation
Ebola and other filoviral haemorrhagic fevers
Bringing a prophylactic Ebola vaccine to licensure
European Health Data and Evidence Network
European Platform for Neurodegenerative Diseases
European regimen accelerator for tuberculosis
EUbOPEN: Enabling and unlocking biology in the OPEN
Framework for clinical trial participants data reutilization for a fully transparent and ethical ecosystem
Novel Gram-negative antibiotic now
Gravitate–Health: Empowering and equipping Europeans with health information for active personal health management and adherence to treatment
H2O Health outcomes observatory
Health initiatives in psoriasis and psoriatic arthritis consortium European states
Identifying digital endpoints to assess fatigue, sleep and activities in daily living in neurodegenerative disorders and immune-mediated inflammatory diseases
Investigating mechanisms and models predictive of accessibility of therapeutics (IM2PACT) into the brain
Integrated immunoprofiling of large adaptive cancer patients cohorts
Specific imaging of immune cell dynamics using novel tracer strategies
Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies
Immune safety avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies
Innovations to accelerate vaccine development and manufacture
Modern approaches for developing antivirals against SARS-CoV 2
New clinical endpoints in primary Sjögren’s syndrome: an interventional trial based on stratifying patients
Optimal treatment for patients with solid tumours in Europe through artificial intelligence
Building a reproducible single-cell experimental workflow to capture tumour drug persistence
Prioritisation and risk evaluation of medicines in the environment
Predicting the impact of monoclonal antibodies & vaccines on antimicrobial resistance
Proton versus photon therapy for esophageal cancer - a trimodality strategy
Real world handling of protein drugs - exploration, evaluation and education
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technologies
Establishing international standards in the analysis of patient reported outcomes and health-related quality of life data in cancer clinical trials
Stratification of obese phenotypes to optimize future obesity therapy
Saracatinib trial to prevent FOP
Accelerating development and improving access to CAR and TCR-engineered T cell therapy
Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
Center of excellence – remote decentralised clinical trials
Imaging biomarkers (IBs) for safer drugs: validation of translational imaging methods in drug safety assessment
Academia and industry united innovation and treatment for tuberculosis
The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
Vaccines and infectious diseases in the ageing population
Combatting bacterial resistance in Europe - molecules against Gram negative infections
Combatting Bacterial Resistance in Europe
New Drugs for Bad Bugs